Pulmonary edema refers to the generation and reflux imbalance of tissue fluid in the lung caused by some reasons, so that a large number of tissue fluid in a very short period of time can not be absorbed by the pulmonary lymphatic and pulmonary vein system, from the pulmonary capillary osmosis, accumulated in the alveoli, lung interstitium and small bronchial, resulting in pulmonary ventilation and ventilation function serious obstacles.
This report contains market size and forecasts of Pulmonary Edema Treatment in Global, including the following market information:
Global Pulmonary Edema Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Pulmonary Edema Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Diagnosis Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Pulmonary Edema Treatment include Pfizer Inc (US), ARGON MEDICAL (US), Edwards Lifesciences Corporation (US), BD (US), Alcaliber S.A. (Spain), Lupin Pharmaceuticals (India), Vitaltec Corporation (China), Medtronic (US) and Koninklijke Philips N.V. (The Netherlands), etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Pulmonary Edema Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pulmonary Edema Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Pulmonary Edema Treatment Market Segment Percentages, by Type, 2021 (%)
Diagnosis
Treatment
Global Pulmonary Edema Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Pulmonary Edema Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals and Clinics
Academic Institutes
Retail Pharmacies
Household
Other
Global Pulmonary Edema Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Pulmonary Edema Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pulmonary Edema Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Pulmonary Edema Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer Inc (US)
ARGON MEDICAL (US)
Edwards Lifesciences Corporation (US)
BD (US)
Alcaliber S.A. (Spain)
Lupin Pharmaceuticals (India)
Vitaltec Corporation (China)
Medtronic (US)
Koninklijke Philips N.V. (The Netherlands)
Siemens Healthcare (Germany)
Hitachi Medical Corporation (US)
Canon Medical Systems Corporation (Japan)